Selective sensitivity of Ewing's Sarcoma to the PARP inhibitor BMN 673

被引：0
|
作者：
Singh, Arun [1 ]
Chmielowski, Bartosz [1 ]
Jia, Weiping [1 ]
Clarke, Kareem [1 ]
O'Brien, Neil [1 ]
Dering, Judy [1 ]
Conklin, Dylan [1 ]
Shen, Yuqiao [2 ]
Post, Leonard [2 ]
Finn, Richard S. [1 ]
Slamon, Dennis J. [1 ]
机构：
[1] Univ Calif Los Angeles, Santa Monica, CA USA
[2] Biomarin, Novato, CA USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-3453
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3453
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The effect of food on the oral bioavailability of the novel PARP 1/2 inhibitor BMN 673 in healthy male subjects
    Henshaw, Joshua
    Zhou, Huiyu
    Musson, Don
    O'Neill, Charles
    Stoltz, Randall
    Dorr, Andrew
    CANCER RESEARCH, 2014, 74 (19)
  • [22] Stability of PARP Inhibition by BMN 673 in Human PBMCs (and Leukaemic Cell Cultures)
    Patterson, M. J.
    Murray, J.
    Curtin, N. J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 106 - 106
  • [23] Incorporating PARP inhibitors in translational studies for Ewing's sarcoma
    Goshorn, David Ross
    Stewart, Elizabeth
    Shelat, Anang
    Dyer, Michael A.
    Bradley, Cori
    Pappo, Alberto S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] In vitro efficacy of a novel dual PARP-HDAC inhibitor in ewing sarcoma
    Truong, Sarah
    Zhai, Beibei
    Ghaidi, Fariba
    Ramos, Louise
    Joshi, Jay
    Brown, Dennis
    Sankar, Neil
    Langlands, John
    Bacha, Jeffrey
    Shen, Wang
    Sorensen, Poul
    Daugaard, Mads
    CLINICAL CANCER RESEARCH, 2022, 28 (18)
  • [25] Combination treatment of PARP inhibitor, BMN 673 and DNMT inhibitor, Azacytidine: A potential therapy for BRCA negative and positive, triple negative breast cancers
    Chowdhury, Khadiza
    Lapidus, Rena G.
    Choi, Eun Yong
    Baylin, Stephen
    Rassool, Feyruz V.
    CANCER RESEARCH, 2015, 75
  • [26] Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations
    Meehan, Robert S.
    Chen, Alice P.
    Coyne, Geraldine O'Sullivan
    Kummar, Shivaani
    Ji, Jiuping
    Vilimas, Rasa
    Juwara, Lamin
    Kinders, Robert J.
    Ferry-Galow, Katherine
    Wilsker, Deborah
    Zhang, Yiping
    Dull, Angie B.
    Navas, Tony
    Wang, Lihua
    Parchment, Ralph E.
    Doroshow, James H.
    CANCER RESEARCH, 2017, 77
  • [27] Stereospecific trapping of PARP-DNA complexes by BMN 673 and comparison with olaparib and rucaparib
    Murai, Junko
    Huang, Shar-yin N.
    Renaud, Amelie
    Zhang, Yiping
    Ji, Jiuping
    Takeda, Shunichi
    Morris, Joel
    Teicher, Beverly
    Doroshow, James H.
    Pommier, Yves
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [28] BMN 673 is a PARP inhibitor in clinical development for the treatment of breast cancer patients with deleterious germline BRCA 1 and 2 mutations
    Mina, L. A.
    Ramanathan, R. K.
    Wainberg, Z. A.
    Byers, L. A.
    Chugh, R.
    Sachdev, J. C.
    Matei, D.
    Zhang, C.
    Henshaw, J. W.
    Dorr, A.
    Kaye, S. B.
    de Bono, J. S.
    CANCER RESEARCH, 2013, 73
  • [29] Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer
    Eskiler, G. Guney
    Cecener, G.
    Egeli, U.
    Tunca, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [30] The PARP inhibitor niraparib demonstrates synergy with chemotherapy in treatment of patient derived Ewing's sarcoma tumorGraft models
    Wilcoxen, Keith M.
    Brooks, David G.
    Tiruchinapalli, Dhanrajan
    Anderson, Nathan
    Donaldson, Rodney
    Nivens, McIver
    Cook, Charlie
    Khor, Tin
    Lu, Bin
    De Oliveira, Elizabeth
    Hawley, Erin
    Bruckheimer, Elizabeth
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
12345